Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists

Journal of Neuroendocrinology

Volumn 13, Issue 8, 2001, Pages 670-677

  Johnson, M P ^a   Kelly, G ^a   Chamberlain, M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Corticosterone; DHPG; Glutamate; LY393675; MGlu

Indexed keywords

1 AMINO 1,3 CYCLOPENTANEDICARBOXYLIC ACID; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 CHLORO 5 HYDROXYPHENYLGLYCINE; 3,5 DIHYDROXYPHENYLGLYCINE; AMINOBUTYRIC ACID DERIVATIVE; CORTICOSTERONE; EGLUMETAD; GLUTAMIC ACID; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; PHOSPHOSERINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOSE RESPONSE; DRUG POTENCY; GABAERGIC SYSTEM; HORMONE RECEPTOR INTERACTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; INTERNEURON; ISOMER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; TIME;

ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE; AMINO ACIDS; ANIMALS; BENZOATES; BICYCLO COMPOUNDS; CORTICOSTERONE; CYCLOLEUCINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; GLYCINE; MALE; NEUROPROTECTIVE AGENTS; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PHENYLACETATES; PROPIONIC ACIDS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RESORCINOLS; XANTHENES;

EID: 0034910994     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2826.2001.00678.x     Document Type: Article

References (38)

1. Glutamate, the dominant excitatory transmitter in neuroendocrine regulation
2. Glutamate: A major excitatory transmitter in neuroendocrine regulation
3. Hypothalamic mechanisms mediating glutamate effects on the hypothalamo-pituitary adrenocortical axis
4. Paraventricular stimulation with glutamate elicits bradycardia and pituitary responses
5. Glutamate and N-methyl-D-aspartate stimulate rat hypothalamic corticotropin-releasing factor secretion in vitro
6. Differential control of glucoregulatory hormone response and glucose metabolism by NMDA and kainate
7. Central NMDA enhances hepatic glucose output and non-insulin-mediated glucose uptake by a nonadrenergic mechanism
8. N-methyl-D-aspartate treatment increases circulating adrenocorticotropin and luteinizing hormone in the rat
9. Effect of central administration of the non-NMDA receptor antagonist DNQX on ACTH and corticosterone release before and during immobilization stress
10. Characterization of the effects of the acute and repeated administration of MK-801 on the release of adrenocorticotropin, corticosterone and prolactin in the rat
11. The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects
12. Effect of memantine alone and with acute 'binge' cocaine on hypothalamic-pituitary-adrenal activity in the rat
13. Subanesthetic effects of the noncompetative NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine response
14. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
15. Metabolic, hormonal, and hemodynamic changes induced by metabotropic excitatory amino acid agonist (1S, 3R)-ACPD
16. Metabotropic glutamate receptor in vasopressin, CRF and VIP hypothalamic neurones
17. Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists
18. (RS)-2-Chloro-5-hydroxphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus
19. Characterisation of [3H]-quisqualate binding to recombinant rat metabotropic metabotropic glutamate 1A & 5A receptors and to rat and human brain sections
20. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors
21. Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors
22. LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats
23. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats
24. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors
25. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity
26. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats
27. Design and characterization of novel group I metabotropic receptor antagonists
28. LY393675, an α-substituted-cyclobutylglycine, ia a potent group I metabotropic glutamate receptor antagonist
29. 2-Methyl-6-(phenylethylnyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist
30. Anticonvulsant action in mice of the novel selective mGluR5 antagonists MPEP and SIB 1893
31. The novel, selective mGlu5 receptor antagonist, 2-methyl-6-(phenylethynyl)-pyridine, reverses mechanical hyperalgesia in rat models of inflammatory pain
32. Local glutamatergic and gabaergic synaptic circuits and metabotropic glutamate receptors in the hypothalamic paraventricular and supraoptic nuclei
33. Presynaptic modulation by metabotropic glutamate receptors of excitatory and inhibitory synaptic inputs to hypothalamic magnocellular neurons
34. Involvement of GABAB receptors in the regulation of the hypothalamo-pituitary-adrenocortical (HPA) axis in rats
35. The effects of GABAA receptor blockade in the dorsomedial hypothalamic nucleus on corticotropin. ACTH and corticosterone secretion in male rats
36. Selective forebrain fiber tract lesions implicate ventral hippocampal structures in tonic regulation of paraventricular nucleus corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) mRNA
37. A temporal study of post-adrenalectomy increase in ACTH secretion in the rat: Effects of various hypothalamic deafferations
38. The role of limbic structures in the modulation of ACTH responses following adrenalectomy